Congratulations on the Day of Defenders of Ukraine!

We sincerely congratulate all men and women - defenders of Ukraine on the holidays - the Day of Defenders of Ukraine and the Intercession of the Blessed Virgin!

These significant dates are inextricably linked and symbolize the connection of generations, an ancient historical tradition, and therefore are especially revered by Ukrainians. We sincerely wish you happiness, joy, kindness and inspiration for successful endeavors for the benefit of the Fatherland. May the unquenchable light of faith unite us and be helped by the high patronage of the Blessed Virgin.

The next batch of tests is already in the area of ​​the Joint Forces Operation

On September 8, representatives of the International Institute for HIV / AIDS and Tuberculosis submitted to the Armed Forces of Ukraine a batch of rapid multi-tests to detect socially dangerous infectious diseases.

More than 6,000 units of test systems for hepatitis B, C, syphilis and HIV were sent to the combat area for further distribution as needed among the military-mobile hospitals performing the assigned tasks.

A drug that can remove HIV from DNA will be tested on humans

The US Food and Drug Administration (FDA) has approved clinical trials of a new human HIV therapy (CRISPR / Cas). This was announced in a press release by ExcisionBioTherapeutics, which will conduct the study.

The developers consider the CRISPR / Cas system to be a "potential cure for chronic HIV." It is expected that this technology can replace standard antiretroviral therapy (ART), which prevents the replication of HIV but does not remove it from the body.

HIV integrates its genetic material into the genome of the host cell, which means that available treatments simply cannot remove it. With CRISPR / Cas technology, DNA can be edited so that the embedded immunodeficiency virus can simply be excised from the genome. This could lead to a complete cure for HIV, experts say.

Before testing a new method of treating HIV in humans, animal testing was performed. A team of scientists from Temple University and the University of Nebraska Medical Center were able to completely remove the HIV virus in some mice (two out of seven) in preclinical trials using a combination of CRISPR + ART. The animals were first given antiretroviral drugs to help reduce HIV and then tested on the CRISPR / Cas system. Experts in the study did not identify side effects that could be associated with therapy.

In parallel, scientists from the Lewis Katz School of Medicine at Temple University tested this technology on primates. The monkeys were first treated with ARV therapy and then given CRISPR / Cas intravenously. Scientists have not been able to completely rid lymph node cells of HIV (the amount of viral DNA has decreased by 38-95%), but the technology has shown its potential. During testing, the researchers found that the therapy penetrates into all tissues of the body where the HIV reservoirs are located.

The next stage is phase I / II human clinical trials, which, according to ExcisionBioTherapeutics, will begin in late 2021. Experts plan to evaluate the effectiveness of different dosages of intravenous CRISPR / Cas, as well as the safety of the drug.

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir

People who start antiretroviral treatment early, before they develop extensive immune system damage, have a smaller HIV viral reservoir, which may improve prospects for a functional cure, according to studies presented this week at the 11th International AIDS Society Conference on HIV Science (IAS 2021).

Very soon after initial infection, HIV establishes a lasting reservoir of inactive virus in long-lived resting T-cells. While antiretroviral drugs can control viral replication, they do not eliminate these latent viral blueprints, which can resume virus production when treatment stops – the key barrier to a cure for HIV.

CD4 count at treatment initiation

Professor Edwina Wright of the University of Melbourne and an international team of colleagues looked at the association between CD4 T-cell count and viral reservoir size in people who began early antiretroviral therapy (ART) in the START (Strategic Timing of Antiretroviral Treatment) trial.

As reported at the 2015 IAS conference, START showed that people who initiate treatment with a CD4 count above 500 cells/mm 3 have a significantly lower risk of illness and death than those who wait until it falls below 350. These findings led to a change in global treatment guidelines to recommend ART for everyone diagnosed with HIV, regardless of CD4 count.

In this substudy, Wright and colleagues compared the size of the viral reservoir in people who started treatment with a CD4 count of 500-599 (36 participants), 600-799 (60 participants) or more than 800 (50 participants) at the time of enrolment. A majority of these participants (60%) were women, most were Black and the median age was approximately 40 years.

Looking at samples collected after about three years on ART, they measured total HIV DNA, a specific type of HIV DNA (2-long terminal repeat DNA) and cell-associated unspliced HIV RNA in CD4 cells, as well as plasma HIV RNA using a single-copy assay. They also assessed markers of T-cell activation (HLA-DR, PD-1 and pSTAT5 expression).

The researchers found that total HIV DNA was lower in people who started treatment with a CD4 count above 800 compared with those who started with 600-799 or 500-599 cells/mm3 (16, 30 and 68 copies per million cells, respectively). While total DNA and plasma HIV RNA were significantly reduced in people who started treatment at the highest CD4 level, this was not the case for 2-long terminal repeat DNA or cell-associated unspliced RNA. T-cell activation as measured by HLA-DR was significantly lower in people who started ART with a CD4 count above 800, but PD-1 and pSTAT5 expression did not differ.

The researchers also noted that older people and women had lower total HIV DNA levels than younger people and men, but the association between lower total DNA and higher CD4 count at ART initiation remained after adjusting for these and other factors. However, when looking at women and men separately, the association was no longer significant for the men.

"Collectively our findings indicate people with HIV who maintain CD4 T cells ≥800 cells/mm3before ART initiation are endowed with an enhanced capacity to eliminate latently infected cells and may constitute a subgroup that could potentially benefit from interventional cure studies," they concluded.

Reservoir size and bNAb susceptibility

In another study, Dr Brian Moldt of Gilead Sciences and colleagues compared viral reservoir size and diversity, as well as HIV's susceptibility to broadly neutralising antibodies (bNAbs), in people who started ART at different stages of infection. Currently being studied in HIV treatment,prevention and cure research, bNAbs are able to recognise conserved parts of the virus that change little across strains.

The study enrolled people in four cohorts based on when they started ART: Fiebig stage I or II (when HIV RNA and the p24 antigen can be detected), Fiebig III or IV (when HIV antibodies are first detectable), late acute infection (three months or less) and chronic infection (over six months). The cohorts included 16, 17, 14 and 17 people, respectively. More than 90% were men, they had been on ART for three to five years and CD4 counts were high (approximately 700 to 900).

The participants underwent leukapheresis, a procedure in which blood is drawn, white blood cells are removed, and the rest of the blood is returned to the body. Through this, the researchers collected a sample of peripheral blood mononuclear cells (T cells and other immune cells). The viral reservoir was measured in these cells using the intact proviral DNA assay, total HIV DNA assay and quantitative viral outgrowth assay. Susceptibility to Gilead's investigational bNAb elipovimab was determined by genotyping of the HIV envelope gene.

The researchers found that total DNA was lower in the Fiebig I-II and Fiebig III-IV groups. The late acute infection cohort had a lower level than the chronic infection cohort, but the difference did not reach statistical significance. What's more, viral diversity was lower in people who started treatment during acute infection compared with chronic infection. People who started ART earlier also generally had greater susceptibility to elipovimab.

"Individuals initiating ART during Fiebig I-IV would be an optimal target population for proof-of-concept cure trials due to smaller, less diverse HIV reservoirs," the researchers concluded.

Post-treatment control in monkeys

Finally, Dr Caroline Passaes of Institut Pasteur in Paris presented results from a study of early antiretroviral therapy and post-treatment control – the ability to maintain viral suppression after stopping therapy – in macaque monkeys.

Dubbed pVISCONTI ('p' for primate), the study used a non-human primate model to assess the impact of early versus late ART initiation on immune responses and outcomes after treatment interruption. The aim is to learn more, under standardised conditions, about the factors underlying viral control seen in people in the French VISCONTI cohort and in other post-treatment controllers.

The researchers looked at monkeys infected with SIV – HIV's simian cousin – comparing 12 animals that started combination ART during primary infection (28 days after exposure), 12 that started during chronic infection (six months post-infection) and 17 that remained untreated. ART continued for two years, then the monkeys were monitored for another six months to a year after treatment interruption. Plasma viral load, CD4 T-cells levels and CD8 T-cell responses were measured throughout the study.

Viral rebound (defined as more than 1000 copies/ml) occurred sooner in those that started treatment during chronic infection compared with primary infection. What's more, 82% of the monkeys in the primary infection group achieved post-treatment control (defined as a viral load below 400 copies/ml) at the end of the study period, compared with 25% in the chronic infection group and 12% in the untreated group.

The researchers also noted that anti-SIV CD8 T-cell activity, which was weak at the time of infection, increased after treatment interruption – particularly in monkeys that started ART during primary infection – and was stronger in post-treatment controllers.

"Early combination ART initiation favoured a delayed viral rebound and a higher frequency of post-treatment control," the researchers concluded. "Post-treatment control was associated with the promotion of a robust secondary SIV-specific CD8 T-cell response, in blood and lymphoid tissues, that efficiently counteracted viral rebound after analytic treatment interruption."




Need to talk to us

Phone: +38 (044) 569 28 52
Fax: +38 (044) 569 28 52
Staronavodnickaya 13A st., office 35.


About us

Back to top
ankara otel şarkı sözleri iç mimarlık ankara rent a car ankara seks izle